BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Reale A, Vitiello A, Conciatori V, Parolin C, Calistri A, Palù G. Perspectives on immunotherapy via oncolytic viruses.Infect Agent Cancer. 2019;14:5. [PMID: 30792754 DOI: 10.1186/s13027-018-0218-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Huang F, Dai C, Zhang Y, Zhao Y, Wang Y, Ru G. Development of Molecular Mechanisms and Their Application on Oncolytic Newcastle Disease Virus in Cancer Therapy. Front Mol Biosci 2022;9:889403. [DOI: 10.3389/fmolb.2022.889403] [Reference Citation Analysis]
2 Wright E, Kawka K, Medina MFC, Latulippe DR. Evaluation of Host Cell Impurity Effects on the Performance of Sterile Filtration Processes for Therapeutic Viruses. Membranes 2022;12:359. [DOI: 10.3390/membranes12040359] [Reference Citation Analysis]
3 Abu Khalaf S, Dandachi D, Granwehr BP, Rodriguez-Barradas MC. Cancer immunotherapy in adult patients with HIV. J Investig Med 2022:jim-2021-002205. [PMID: 35086858 DOI: 10.1136/jim-2021-002205] [Reference Citation Analysis]
4 Reale A, Calistri A, Altomonte J. Giving Oncolytic Viruses a Free Ride: Carrier Cells for Oncolytic Virotherapy. Pharmaceutics 2021;13:2192. [PMID: 34959474 DOI: 10.3390/pharmaceutics13122192] [Reference Citation Analysis]
5 Santos Apolonio J, Lima de Souza Gonçalves V, Cordeiro Santos ML, Silva Luz M, Silva Souza JV, Rocha Pinheiro SL, de Souza WR, Sande Loureiro M, de Melo FF. Oncolytic virus therapy in cancer: A current review. World J Virol 2021; 10(5): 229-255 [PMID: 34631474 DOI: 10.5501/wjv.v10.i5.229] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
6 Qiu W, Ding X, Li S, He Y, Zhu L. Oncolytic Bovine Herpesvirus 1 Inhibits Human Lung Adenocarcinoma A549 Cell Proliferation and Tumor Growth by Inducing DNA Damage. Int J Mol Sci 2021;22:8582. [PMID: 34445287 DOI: 10.3390/ijms22168582] [Reference Citation Analysis]
7 Uche IK, Kousoulas KG, Rider PJF. The Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor Microenvironment. Viruses 2021;13:1200. [PMID: 34206677 DOI: 10.3390/v13071200] [Reference Citation Analysis]
8 Wang X, Zhao X, He Z. Mesenchymal stem cell carriers enhance anti-tumor efficacy of oncolytic virotherapy. Oncol Lett 2021;21:238. [PMID: 33664802 DOI: 10.3892/ol.2021.12499] [Reference Citation Analysis]
9 Guo X, Shen W. Latest evidence on immunotherapy for cholangiocarcinoma.Oncol Lett. 2020;20:381. [PMID: 33154779 DOI: 10.3892/ol.2020.12244] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
10 Hwang YJ, Myung H. Engineered Bacteriophage T7 as a Potent Anticancer Agent in vivo. Front Microbiol 2020;11:491001. [PMID: 33072000 DOI: 10.3389/fmicb.2020.491001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Sun J, Gastman BR, McCahon L, Buchbinder EI, Puzanov I, Nanni M, Lewis JM, Carvajal RD, Singh-Kandah S, Desai AM, Raskin L, Nielson CM, Ismail R, Zager JS. Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2). Melanoma Manag 2020;7:MMT41. [PMID: 32821373 DOI: 10.2217/mmt-2020-0005] [Reference Citation Analysis]
12 Kim Y, Gil J, Pla I, Sanchez A, Betancourt LH, Lee B, Appelqvist R, Ingvar C, Lundgren L, Olsson H, Baldetorp B, Kwon HJ, Oskolás H, Rezeli M, Doma V, Kárpáti S, Szasz AM, Németh IB, Malm J, Marko-Varga G. Protein Expression in Metastatic Melanoma and the Link to Disease Presentation in a Range of Tumor Phenotypes. Cancers (Basel) 2020;12:E767. [PMID: 32213878 DOI: 10.3390/cancers12030767] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 McKenna MK, Rosewell-Shaw A, Suzuki M. Modeling the Efficacy of Oncolytic Adenoviruses In Vitro and In Vivo: Current and Future Perspectives. Cancers (Basel) 2020;12:E619. [PMID: 32155969 DOI: 10.3390/cancers12030619] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Wang Z, Zhi K, Ding Z, Sun Y, Li S, Li M, Pu K, Zou J. Emergence in protein derived nanomedicine as anticancer therapeutics: More than a tour de force. Semin Cancer Biol 2021;69:77-90. [PMID: 31962173 DOI: 10.1016/j.semcancer.2019.11.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
15 Zheng M, Huang J, Tong A, Yang H. Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances.Mol Ther Oncolytics. 2019;15:234-247. [PMID: 31872046 DOI: 10.1016/j.omto.2019.10.007] [Cited by in Crossref: 92] [Cited by in F6Publishing: 75] [Article Influence: 30.7] [Reference Citation Analysis]
16 Andtbacka RHI, Amatruda T, Nemunaitis J, Zager JS, Walker J, Chesney JA, Liu K, Hsu CP, Pickett CA, Mehnert JM. Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma. EBioMedicine 2019;47:89-97. [PMID: 31409575 DOI: 10.1016/j.ebiom.2019.07.066] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]